Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 3 Interventional

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

ClinicalTrials.gov ID: NCT07664553

Public ClinicalTrials.gov record NCT07664553. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Aug 2, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)

Study identification

NCT ID
NCT07664553
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
600 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 5, 2026
Primary completion
May 22, 2028
Completion
May 22, 2028
Last update posted
Jun 23, 2026

2026 – 2028

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Research Site Little Rock Arkansas 72205
Research Site Lincoln California 95648
Research Site Aurora Colorado 80045
Research Site Ocoee Florida 34761
Research Site Decatur Georgia 30030
Research Site Potomac Maryland 20854
Research Site Cary North Carolina 27518
Research Site Morehead City North Carolina 28557
Research Site Myrtle Beach South Carolina 29572
Research Site Memphis Tennessee 38119
Research Site Houston Texas 77040
Research Site San Antonio Texas 78231
Research Site Renton Washington 98057

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 107 non-U.S. sites.

Recently updated Type 2 Diabetes Mellitus trials

Other public records listing Type 2 Diabetes Mellitus. Sorted by last update posted; newest first. Not a recommendation.

All Type 2 Diabetes Mellitus trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07664553, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 23, 2026 · Synced Aug 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07664553 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →